Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.
Treatment Action Group (TAG) is urging caution regarding the use of antiretroviral (ART) drugs as treatments for SARS-CoV-2/COVID-19. While there is clearly an acute need to carefully and quickly study interventions that may have activity against SARS-CoV-2, the virus which causes COVID-19 disease, it’s vitally important to be aware of the information that is currently available.
Due to the late cancellation of the in-person Conference on Retroviruses and Opportunistic Infections (CROI), the 2020 Pre-CROI Community HIV Cure Research Workshop took place via Zoom conference on Saturday, March 7th. We thank all presenters, panelists and participants -…
This report aims to make more accessible to community advocates discussions around ethical conduct of biomedical prevention trials in the era of PrEP. In early 2019, TAG, along with Black AIDS Institute and the HIV Vaccine Trials Network developed an…
A resource listing of articles, reports, websites, and ongoing clinical trials related to the research effort to cure HIV infection.
Tuberculosis (TB) is the number one killer of people living with HIV/AIDS, causing one in three of all AIDS-related deaths. People living with HIV are at increased risk of developing TB, and of dying from it—especially when they have advanced…
The ACT NOW:END AIDS Coalition, of which TAG is a founding member, released this statement today calling for the administration’s efforts to end the HIV epidemic to be rooted in fact, science, and sensible policies that are consistent with the stated goal of ending HIV.
Treatment Action Group acknowledges with profound disappointment today’s announcement that the HIV Vaccine Trials Network HVTN 702 study did not demonstrate efficacy in preventing HIV acquisition.